BofA raised the firm’s price target on Lenz Therapeutics (LENZ) to $38 from $37 and keeps a Buy rating on the shares following a Q4 update that the firm notes was “mainly focused” on the pending approval and launch of LNZ100 for treatment of presbyopia. The firm, which continues to expect timely approval in August followed by a launch in Q4 of 2025, cites updated cash and share count estimates for its refined price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- LENZ Therapeutics: Innovative Presbyopia Treatment and Strategic Growth Reinforce Buy Rating
- Promising Outlook for LENZ Therapeutics: Buy Rating Backed by Strategic Marketing and Anticipated FDA Approval
- Lenz Therapeutics price target raised to $47 from $44 at Citi
- Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid FDA Progress and Commercial Readiness
- Buy Rating for LENZ Therapeutics Driven by Promising LNZ100 Eye Drop Prospects